Abstracts tagged "osteoporosis"

Abstract Number: 0356 • ACR Convergence 2025
An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
Stephen Poos¹, Hoang Nguyen², Samuel Greenberg³, Marcus Lee², Heidi Roppelt¹ and Asha Patnaik², ¹Stony Brook Southampton Hospital, Southampton, NY, ²Stony Brook University Hospital, Stony Brook, NY, ³Renaissance School of Medicine at Stony Brook University, Stony Brook, NY
Background/Purpose: Osteoporosis is under screened in men. The United States Preventive Services Task Force (USPSTF) does not publish guidelines for osteoporosis screening in men. Other…
Abstract Number: 0338 • ACR Convergence 2025
Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
Andriko Palmowski¹, Tobias Haugegaard², Ingiäld Hafstörm³, Henning Bliddal⁴, Judith Oldenkott⁵, Siegfried Wassenberg⁶, Ernest Choy⁷, John Kirwan⁸, Robin Christensen⁹, Maarten Boers¹⁰ and FRANK BUTTGEREIT¹¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Kopenhagen, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴The Parker Institute, Frederiksberg, Denmark, ⁵Charité, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁸University of Bristol, Bristol, United Kingdom, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Hovedstaden, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹¹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: It is unclear to what extent low dose glucocorticoids (GCs) impact bone health in patients with rheumatoid arthritis (RA). RA leads to bone loss…
Abstract Number: 2595 • ACR Convergence 2025
Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Edgar Wiebe¹, Claire-Felicia Liebich², Dörte Huscher³, Lien Meerkatt⁴, Andriko Palmowski⁵, Sandra Hermann¹, Burkhard Muche⁵, Zhivana Boyadzhieva², Gerhard Krönke⁶, Bernd Wolfarth² and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Physical exercise helps maintain bone mineral density (BMD), prevent falls, and reduce fracture risk. Strength and weight-bearing exercises are particularly effective. However, individuals with…
Abstract Number: 2110 • ACR Convergence 2025
Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Edgar Wiebe¹, Kerstin Rubarth², Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche⁴, Gerhard Krönke⁵, Andriko Palmowski⁴ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures due to systemic inflammation and glucocorticoid (GC)…
Abstract Number: 0355 • ACR Convergence 2025
Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy
Soukayna Baddi¹, Suarez Dimitri¹, Alexis Ruet¹, Theo Van Butsel¹, Damiano Cerasuolo¹, Jean-Matthieu L’Orphelin¹ and Anne-Christine Rat², ¹Caen University Hospital, Caen, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France
Background/Purpose: The use of immune checkpoint inhibitors (ICIs) is becoming increasingly important in the management of melanoma. However, although ICIs are associated with various immune-related…
Abstract Number: 0337 • ACR Convergence 2025
Bridging the Bone Gap: A Quality Improvement Project on Osteoporosis Screening Practices in a Teaching Institution
Aakanksha Pitliya¹, Alexandra Georgiana Boc², Hema Latha Anam², Richard Oletsky², Dipabali Chaudhuri² and Rajesh Thirumaran², ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Osteoporosis remains underdiagnosed despite clear guidelines. As primary care physicians and trainees are key to preventive care, this quality improvement (QI) project aimed to…
Abstract Number: 2593 • ACR Convergence 2025
Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study
Karel Pavelka¹, Frank Schneider², Deepak S³, Bracha Timan⁴, Hadas Barkay⁴ and Anton Buchner², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Teva GmbH, Ulm, Germany, ³Teva Pharma India Private Limited, Bangalore, India, ⁴Teva Pharmaceutical Industries Ltd., Netanya, Israel
Background/Purpose: TVB-009 is being developed as a proposed biosimilar candidate to the reference denosumab. Biosimilarity of TVB-009 to US-licensed denosumab (US-denosumab) and EU-approved denosumab was…
Abstract Number: 2109 • ACR Convergence 2025
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Edgar Wiebe¹, Lien Meerkatt², Andriko Palmowski³, Zhivana Boyadzhieva⁴, Kerstin Rubarth⁵, Sandra Hermann¹, Burkhard Muche³, Gerhard Krönke⁶ and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Individuals with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are at increased risk for osteoporosis and fragility fractures due to long-term glucocorticoid (GC)…
Abstract Number: 0353 • ACR Convergence 2025
Incidence of Clinical Fragility Fractures and Mortality in Patients with Rheumatoid Arthritis Treated with Rituximab
Montserrat Roig Kim¹, Carla Marco-Pascual², Martí Aguilar-Coll¹, Javier Narváez³, Joan Miquel Nolla¹ and Carmen Gomez Vaquero⁴, ¹Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, ⁰⁸⁹⁰⁷ L'Hospitalet, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have an increased risk of osteoporosis and fragility fractures. Bone loss in RA is multifactorial and mainly determined by…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 2594 • ACR Convergence 2025
Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis
Karel Pavelka¹, Frank Schneider², Deepak S³, Bracha Timan⁴, Hadas Barkay⁴ and Anton Buchner², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Teva GmbH, Ulm, Germany, ³Teva Pharma India Private Limited, Bangalore, India, ⁴Teva Pharmaceutical Industries Ltd., Netanya, Israel
Background/Purpose: TVB-009 is being developed as a proposed biosimilar candidate to the reference denosumab. Denosumab is a human IgG2 monoclonal antibody that binds to the…
Abstract Number: 2108 • ACR Convergence 2025
Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
César Antonio Egües Dubuc¹, Nerea Alcorta Lorenzo², Esther Laso Lucas³, Carlos Maria Lizasoain Alustiza⁴, Claudia Murillo Erazo³, Gabriela Jimenez Clemente³, Gaspar de La Herran Nuñez⁴, Vicente Lavilla Garcia³, Imanol Gabarain Morcillo⁴, Leire Unanue Pumar⁴, Irene Corcuera Elosegui⁴, Antonio Martin Garcia⁴, Jorge Jesus Cancio Fanlo⁵, Maria Ariztia Sarratea³, Ander Alberdi Arbelaiz⁴, Iñaki Maria Arruabarrena Echeverria³, Elena Zubillaga Azpiroz⁴ and LUIS LOPEZ DOMINGUEZ⁶, ¹Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ²University Hospital Donostia, san sebastian, Spain, ³Matia Hospital, San Sebastian, Pais Vasco, Spain, ⁴Donostia University Hospital, San Sebastian, Pais Vasco, Spain, ⁵Donostia University Hospital, San Sebastian, ⁶Hospital Universitario Donostia, San Sebastian, Spain
Background/Purpose: Our Fracture Coordination Unit operates across two hospitals: University Hospital of Donostia (UHD) and Matía Hospital (MH). Patients with a geriatric profile are transferred…
Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Marshall Weber¹, William Obremskey², Jared Huling³, Nitya Shah³, Emily Budde⁴, Zhiping Huo⁴, Reside Jacob⁴, Brinda Basida¹, Colton Hoffer¹, Binni Makkar⁵ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²Vanderbilt University, Nashville, TN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴Center of Innovation for Complex Chronic Healthcare, Washington DC, DC, ⁵University of Kentucky, Lexington, KY
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 2592 • ACR Convergence 2025
Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Giovanni Adami¹, Francesco Pollastri², Angelo Fassio², Camilla Benini², Davide Gatti², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Transition from long-term denosumab to PTH-analogs or romosozumab might expose patients to the risk of the so-called rebound phenomenon. Adding romosozumab to denosumab might…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].